Enthera Overview

  • Founded

  • 2016

Founded
  • Status

  • Private

  • Employees

  • 15

Employees
  • Latest Deal Type

  • Series A

  • Latest Deal Amount

  • $42.6M

  • Investors

  • 9

Enthera General Information

Description

Developer of biotherapeutics intended to treat auto-immune disorders. The company's pipelined products target pathways involved in cell apoptosis in the gut, pancreas, and other organs which plays a key role in the development of type 1 diabetes and inflammatory bowel disease, enabling the medical community to effectively combat intractable autoimmune diseases.

Contact Information

Website
www.entherapharmaceuticals.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Via Gioberti, 8
  • 20123 Milan(Lombardy)
  • Italy
+39 02 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enthera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 28-Jan-2021 $42.6M 000.00 Completed Pre-Clinical Trials
3. Seed Round 24-Jul-2018 00.000 00.000 Completed Pre-Clinical Trials
2. Early Stage VC 10-May-2018 Completed Pre-Clinical Trials
1. Seed Round 01-Oct-2016 Completed Pre-Clinical Trials
To view Enthera’s complete valuation and funding history, request access »

Enthera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biotherapeutics intended to treat auto-immune disorders. The company's pipelined products target pathways i
Drug Discovery
Milan, Italy
15 As of 2022
000.00
00000000000 000.00

000000

dipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqu
0000 000000000
Cambridge, MA
000
00.00 0000-00-00
00000000000 000

000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim ven
0000 000000000
South San Francisco, CA
0 As of 0000
00000
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enthera Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Venture Capital-Backed Cambridge, MA 000 00000000000 000
000000 00000000000 Formerly VC-backed South San Francisco, CA 0 00000 000000&0 00000
0000000 0000000000 Private Equity-Backed Needham, MA 00 00000 000000000000 00000
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
0000000 0000000000 Formerly VC-backed Burlington, MA 0 00000 000000000 00000
You’re viewing 5 of 32 competitors. Get the full list »

Enthera Patents

  • 9

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Enthera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021225061-A1 Inhibitors and uses thereof Pending 20-Feb-2020 000000000
CA-3162043-A1 Inhibitors and uses thereof Pending 20-Feb-2020 000000000
EP-3868396-A1 Inhibitors and uses thereof Inactive 20-Feb-2020 000000000
EP-4106804-A1 Inhibitors and uses thereof Pending 20-Feb-2020 000000000
CA-3154017-A1 Igfbp3 antibodies and therapeutic uses thereof Pending 21-Nov-2019 C07K16/18
To view Enthera’s complete patent history, request access »

Enthera Executive Team (8)

Name Title Board Seat Contact Info
Aled Williams Chief Executive Officer & Board Member
Lucia Reggi Financial Director
Francesca D'Addio Ph.D Co-Founder & Head of Preclinical Research
Silvano Spinelli Co-Founder & Chairman
Antonio Speziale Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Enthera Board Members (11)

Name Representing Role Since
Aled Williams Enthera Chief Executive Officer & Board Member 000 0000
Anta Gkelou Ph.D Sofinnova Partners Board Observer 000 0000
Carole Nuechterlein JD Roche Venture Fund Board Member 000 0000
Graziano Seghezzi Sofinnova Partners Board Member 000 0000
Katie Elias Self Board Observer 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Enthera Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enthera Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Banca Profilo PE-Backed Company Minority 000 0000 000000 0
Banor Sim Asset Manager Minority 000 0000 000000 0
Roche Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Juvenile Diabetes Research Foundation Limited Partner Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial